company,name,title,link
Intellia Therapeutics,Intellia Therapeutics,FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics,https://ir.intelliatx.com/news-releases/news-release-details/fda-accepts-investigational-new-drug-application-crisprcas9
Beam Therapeutics,Beam Therapeutics,Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results,https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-reports-business-updates-and-full-year-2019
Bluebird Bio,Bluebird Bio,"Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA",http://investor.bluebirdbio.com/news-releases/news-release-details/bristol-myers-squibb-and-bluebird-bio-announce-submission
Bluebird Bio,Bluebird Bio,"bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development",http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-provides-assessment-impact-covid-19-update-business
Sarepta Therapeutics,Sarepta Therapeutics,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-51
RegenxBio,RegenxBio,REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder,http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-and-ultragenyx-announce-new-license-agreement-use-navr
Orchard Therapeutics,Orchard Therapeutics,Orchard Therapeutics Outlines Business Impact of COVID-19,https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-outlines-business-impact-covid-19
Axovant Gene Therapies,Axovant Gene Therapies,Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing and Accelerate Diagnoses of GM1 and GM2 Gangliosidosis,http://investors.axovant.com/news-releases/news-release-details/axovant-announces-partnership-invitae-increase-access-genetic
Axovant Gene Therapies,Axovant Gene Therapies,Axovant Provides Business and Operations Update During the COVID-19 Pandemic,http://investors.axovant.com/news-releases/news-release-details/axovant-provides-business-and-operations-update-during-covid-19
Axovant Gene Therapies,Axovant Gene Therapies,Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day,http://investors.axovant.com/news-releases/news-release-details/axovant-participate-guggenheim-healthcare-talks-genomic
Passage Bio,Passage Bio,Passage Bio to Present at 19th Annual Needham Healthcare Conference,https://investors.passagebio.com/news-releases/news-release-details/passage-bio-present-19th-annual-needham-healthcare-conference
Passage Bio,Passage Bio,Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day,https://investors.passagebio.com/news-releases/news-release-details/passage-bio-participate-guggenheim-healthcare-talks-genomic
Rocket Pharmaceuticals,Rocket Pharmaceuticals,Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic,https://rocketpharmaceuticals.gcs-web.com/news-releases/news-release-details/rocket-pharmaceuticals-provides-business-update-light-covid-19
Rocket Pharmaceuticals,Rocket Pharmaceuticals,Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day,https://rocketpharmaceuticals.gcs-web.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-participation-guggenheim
Rocket Pharmaceuticals,Rocket Pharmaceuticals,Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease,https://rocketpharmaceuticals.gcs-web.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-science-translational-medicine
Decibel Therapeutics,Decibel Therapeutics,Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss Associated with Cisplatin Chemotherapy,https://www.decibeltx.com/decibel-therapeutics-publishes-results-from-early-stage-study-prevent-hearing-loss-associated-cisplatin-chemotherapy/
Allogene Therapeutics,Allogene Therapeutics,Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences,https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-announces-participation-two-upcoming
Unity Biotechnology,Unity Biotechnology,UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101,http://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-completes-enrollment-phase-1b-study-ubx0101
Unity Biotechnology,Unity Biotechnology,UNITY Biotechnology Announces Start of New CEO and New Employment Inducement Grants,http://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-announces-start-new-ceo-and-new-employment
resTOR Bio,resTOR Bio,resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand,https://ir.restorbio.com/news-releases/news-release-details/restorbio-announces-delay-its-ongoing-phase-1b2a-trial-rtb101
Harpoon Therapeutics,Harpoon Therapeutics,Harpoon Therapeutics Appoints Two New Members to Its Board of Directors,https://ir.harpoontx.com/news-releases/news-release-details/harpoon-therapeutics-appoints-two-new-members-its-board
Cabaletta Therapeutics,Cabaletta Therapeutics,Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update,https://investors.cabalettabio.com/news-releases/news-release-details/cabaletta-bio-reports-fourth-quarter-and-full-year-2019
TCR2 Therapeutics,TCR2 Therapeutics,TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors,http://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-announces-immuno-oncology-pioneer-dr-axel-hoos
TCR2 Therapeutics,TCR2 Therapeutics,TCR² Therapeutics to Present at the Goldman Sachs Cell Therapy Day,http://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-present-goldman-sachs-cell-therapy-day
TCR2 Therapeutics,TCR2 Therapeutics,TCR² Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update,http://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-reports-fourth-quarter-and-full-year-2019
AgeX Therapeutics,AgeX Therapeutics,,https://investors.agexinc.com/news/news-details/2020/AgeX-Therapeutics-Reports-Fourth-Quarter-and-Annual-2019-Financial-Results-and-Provides-Business-Update/default.aspx
AgeX Therapeutics,AgeX Therapeutics,,https://investors.agexinc.com/news/news-details/2020/AgeX-Therapeutics-Licensee-ImStem-Biotechnology-Announces-FDA-has-Lifted-the-Hold-and-Cleared-the-Investigational-New-Drug-Application-for-IMS001-for-the-Treatment-of-Multiple-Sclerosis/default.aspx
Moderna,Moderna,Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus,https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-award-us-government-agency-barda-483-million
Moderna,Moderna,Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day,https://investors.modernatx.com/news-releases/news-release-details/moderna-highlights-opportunity-mrna-vaccines-its-first-vaccines
Moderna,Moderna,Moderna Announces that Its 2020 Annual Meeting of Stockholders Will be Held in Virtual Format,https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-its-2020-annual-meeting-stockholders-will-be
Moderna,Moderna,Moderna to Present at 19th Annual Needham Healthcare Conference,https://investors.modernatx.com/news-releases/news-release-details/moderna-present-19th-annual-needham-healthcare-conference
Moderna,Moderna,"Moderna to Host Virtual Vaccines Day on April 14, 2020",https://investors.modernatx.com/news-releases/news-release-details/moderna-host-virtual-vaccines-day-april-14-2020
Moderna,Moderna,Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development,https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-update-impact-covid-19-business-operations-and
Moderna,Moderna,Moderna to Present at MIT Lecture Series,https://investors.modernatx.com/news-releases/news-release-details/moderna-present-mit-lecture-series
Vir Bio,Vir Bio,VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial,https://investors.vir.bio/news-releases/news-release-details/vir-2218-demonstrates-dose-dependent-and-durable-reductions
Vir Bio,Vir Bio,Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment,https://investors.vir.bio/news-releases/news-release-details/samsung-biologics-and-vir-biotechnology-enter-agreement-large
Vir Bio,Vir Bio,Vir Biotechnology to Host Key Opinion Leader Call and Present Update on  Phase 1/2 HBV Clinical Trial with siRNA VIR-2218,https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-host-key-opinion-leader-call-and-present
Vir Bio,Vir Bio,GSK and Vir Biotechnology enter collaboration to find coronavirus solutions,https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus
Vir Bio,Vir Bio,Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19,https://investors.vir.bio/news-releases/news-release-details/vir-and-alnylam-expand-collaboration-advance-investigational
Vir Bio,Vir Bio,Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19,https://investors.vir.bio/news-releases/news-release-details/generation-bio-and-vir-biotechnology-collaborate-research
Vir Bio,Vir Bio,Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results,https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-provides-corporate-update-and-reports-fourth
Vir Bio,Vir Bio,Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19,https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-proceeding-two-clinical-development-candidates
Blueprint Medicines,Blueprint Medicines,Blueprint Medicines Announces the Achievement of Key Portfolio Milestones,http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-achievement-key-portfolio
Ideaya Biosciences,Ideaya Biosciences,"IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update",https://ir.ideayabio.com/news-releases/news-release-details/ideaya-biosciences-inc-reports-fourth-quarter-2019-financial
